Genetic Testing for Cancer Risk

Genetic testing for cancer risk examines inherited DNA variants that may substantially elevate a person's lifetime probability of developing specific malignancies. This page covers the major test types, how laboratory analysis translates raw sequencing data into clinical risk categories, the scenarios that most commonly prompt referral, and the decision boundaries that distinguish hereditary cancer syndromes from sporadic disease. Understanding the regulatory and clinical framework around these tests is essential context for anyone navigating a cancer screening or diagnostic pathway.

Definition and scope

Germline genetic testing for cancer risk identifies pathogenic or likely pathogenic variants in genes transmitted through the germline — meaning the variant is present in every cell of the body and can be passed to biological children. This distinguishes it from somatic testing, which detects mutations acquired only within tumor cells and does not reflect inherited risk (covered in detail at molecular profiling and biomarkers).

The U.S. Food and Drug Administration (FDA) regulates genetic tests as medical devices under 21 CFR Part 820, while laboratory operations fall under the Clinical Laboratory Improvement Amendments (CLIA), administered by the Centers for Medicare and Medicaid Services (CMS). The FDA's 2023 Proposed Rule on Laboratory Developed Tests proposed extending premarket review to laboratory-developed tests, a category that includes most hereditary cancer panels. The genetic privacy framework governing these results — specifically prohibiting health insurers from using genetic test results in coverage or premium decisions — is established by the Genetic Information Nondiscrimination Act of 2008 (GINA).

Hereditary cancer syndromes account for an estimated 5 to 10 percent of all cancer diagnoses, according to the National Cancer Institute (NCI). The remaining 90 to 95 percent arise from somatic mutations, environmental exposures, or polygenic risk accumulation not attributable to single high-penetrance variants.

How it works

Germline testing begins with a biological sample — most commonly a blood draw or saliva collection — from which genomic DNA is extracted. The laboratory then applies one or more analytical methods:

1. Single-gene sequencing — targets one gene entirely (e.g., full BRCA1 sequencing) when clinical presentation strongly implicates a specific locus.
2. Multi-gene panel testing — simultaneously sequences 25 to 80 or more cancer-associated genes; panels vary by laboratory and clinical focus (breast/ovarian, colorectal, pan-cancer).
3. Large rearrangement analysis (MLPA) — detects deletions or duplications spanning multiple exons that standard sequencing misses; often run alongside sequencing for genes like BRCA1, BRCA2, and MLH1.
4. Variant classification — laboratories report variants using the five-tier American College of Medical Genetics and Genomics (ACMG) classification: Pathogenic, Likely Pathogenic, Variant of Uncertain Significance (VUS), Likely Benign, and Benign. Only Pathogenic and Likely Pathogenic findings drive clinical management changes.

Turnaround time for commercial panels ranges from approximately 2 to 4 weeks. Results are communicated through a written laboratory report, which a certified genetic counselor or clinician is expected to interpret in the context of the patient's personal and family history and genetic counseling data.

The National Society of Genetic Counselors (NSGC) publishes practice guidelines on pre- and post-test counseling, emphasizing that results — particularly VUS findings — require careful contextualization to avoid inappropriate clinical responses.

Common scenarios

Genetic testing for inherited cancer risk is most frequently initiated in four clinical contexts:

• Known familial variant — a first- or second-degree relative carries a confirmed pathogenic variant, and cascade testing is offered to identify at-risk relatives. This is the highest-yield scenario; the pre-test probability of carrying the same variant is 50 percent for a first-degree relative.
• Personal cancer diagnosis with suspicious features — early age at diagnosis (breast cancer before age 45, colorectal cancer before age 50), bilateral disease, multiple primary tumors, or a tumor histology associated with hereditary syndromes (e.g., triple-negative breast cancer, sebaceous adenoma in Lynch syndrome).
• Population-based screening in high-risk ancestries — Ashkenazi Jewish ancestry confers founder variant prevalence of approximately 1 in 40 for BRCA1/2, compared with approximately 1 in 400 in the general population (NCI).
• Surveillance-guided risk management — individuals with confirmed pathogenic variants in MLH1, MSH2, MSH6, or PMS2 (Lynch syndrome) follow structured colonoscopy intervals per guidelines from the U.S. Multi-Society Task Force on Colorectal Cancer, recommending colonoscopy every 1 to 2 years beginning at age 20 to 25.

Decision boundaries

The distinction between high-penetrance, moderate-penetrance, and low-penetrance variants determines the clinical management pathway chosen in collaboration with an oncologist or genetic counselor (for regulatory framing of that clinical environment, see regulatory context for oncology).

High-penetrance variants — including pathogenic BRCA1, BRCA2, TP53 (Li-Fraumeni syndrome), CDH1 (hereditary diffuse gastric cancer), and Lynch syndrome genes — confer lifetime cancer risk that often exceeds 50 to 80 percent for specific cancer types. These findings typically prompt intensified surveillance, prophylactic surgical consideration, or chemoprevention discussions.

Moderate-penetrance variants — such as pathogenic CHEK2, ATM, and PALB2 — carry relative risk elevations of approximately 2- to 4-fold above population baseline. Clinical management is less standardized; guidelines from the National Comprehensive Cancer Network (NCCN) are updated annually and stratify recommendations by variant and family history context.

Variants of Uncertain Significance — VUS findings, which constitute a substantial proportion of results returned on large multi-gene panels, do not warrant clinical management changes at the time of reporting. Laboratories reclassify variants as evidence accumulates; patients and clinicians are expected to be notified of reclassifications that change a result from VUS to Pathogenic or Benign.

Polygenic risk scores (PRS), which aggregate small-effect variants across hundreds of loci, are emerging as a complementary layer of risk stratification but remain outside standard clinical guideline recommendations as of their most recent NCCN publication cycles.

References

• National Cancer Institute — Genetic Testing for Inherited Cancer Susceptibility Syndromes
• National Cancer Institute — BRCA Gene Mutations: Cancer Risk and Genetic Testing
• U.S. Food and Drug Administration — 21 CFR Part 820, Quality System Regulation
• FDA Proposed Rule on Laboratory Developed Tests, Federal Register 2023
• Centers for Medicare and Medicaid Services — Clinical Laboratory Improvement Amendments (CLIA)
• U.S. Equal Employment Opportunity Commission — Genetic Information Nondiscrimination Act (GINA)
• American College of Medical Genetics and Genomics (ACMG)
• National Society of Genetic Counselors (NSGC)
• National Comprehensive Cancer Network (NCCN) — Genetic/Familial High-Risk Assessment Guidelines
• U.S. Multi-Society Task Force on Colorectal Cancer — Lynch Syndrome Surveillance Guidelines

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)